Evidence map›Paper›PMID 30941241›Full record

ArticleJournal of breast cancer2019

Durable Response of Androgen Receptor-Positive Male Breast Cancer to Goserelin.

Hamdy Abdel Azim, Loay Kassem, Kyrillus Samaan Shohdy, Boules Eshaak, Shady Elia Anis, Nermine Shawky Kamal

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of breast cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Neoadjuvant treatment for male breast cancer.Translational cancer research · 2023
    Article
  3. Article
  4. Review
  5. Breast cancer in a transgender man.CA: a cancer journal for clinicians
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hamdy Abdel AzimDepartment of Clinical Oncology, Kasr Alainy School of Medicine, Cairo University, Cairo, Egypt.
Loay KassemDepartment of Clinical Oncology, Kasr Alainy School of Medicine, Cairo University, Cairo, Egypt.ORCID 0000-0001-6559-5867
Kyrillus Samaan ShohdyDepartment of Clinical Oncology, Kasr Alainy School of Medicine, Cairo University, Cairo, Egypt.
Boules EshaakDepartment of Clinical Oncology, Cairo Oncology Center, Cairo, Egypt.ORCID 0000-0003-2668-0035
Shady Elia AnisDepartment of Pathology, Kasr Alainy School of Medicine, Cairo University, Cairo, Egypt.ORCID 0000-0001-6543-8060
Nermine Shawky KamalDepartment of Clinical Oncology, Cairo Oncology Center, Cairo, Egypt.ORCID 0000-0001-5306-4209

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The luteinizing hormone-releasing hormone/androgen receptor (LHRH/AR) pathway is a promising treatment target in a subgroup of female patients with triple-negative breast cancer (TNBC). However, very little is known about the efficacy of this strategy in male patients with TNBC. In this report, we describe a male patient with AR-positive TNBC who was successfully treated using an LHRH agonist after pretreatment with several lines of chemotherapy and achieved a durable response. We also review the existing evidence supporting LHRH- and AR-targeted therapy for this rare disease.

Indexed as

Androgen receptorLuteinizing hormone-releasing hormoneTriple-negative breast neoplasms

Identifiers

PMID30941241
PMCPMC6438837

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.